- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06840782
Standard di cura basato sull'immunoterapia di prima linea e trattamenti ablativi locali per i pazienti con carcinoma polmonare non a piccole cellule oligometastatiche. (OliGRAIL)
Standard di cura basato sull'immunoterapia di prima linea e trattamenti ablativi locali per pazienti con carcinoma polmonare non a piccole cellule oligometastatiche: uno studio randomizzato, multicentrico di fase III in aperto
First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Antonin LEVY
- Numero di telefono: 01 42 11 47 57
- Email: antonin.levy@gustaveroussy.fr
Luoghi di studio
-
-
-
Caen, Francia, 14076
- Reclutamento
- Centre François Baclesse
-
Contatto:
- Mathieu CESAIRE
- Numero di telefono: 02 31 45 50 50
- Email: m.cesaire@baclesse.unicancer.fr
-
Lille, Francia, 59000
- Reclutamento
- Centre Oscar Lambret
-
Contatto:
- Florence LE TINIER
- Numero di telefono: 03 20 29 59 59
- Email: f-letinier@o-lambret.fr
-
Lyon, Francia, 69000
- Reclutamento
- Hospices Civils de Lyon (HCL)
-
Contatto:
- Thomas PIERRET
- Numero di telefono: 04 27 85 77 00
- Email: thomas.pierret@chu-lyon.fr
-
Nice, Francia, 06001
- Reclutamento
- CHU Nice
-
Contatto:
- Jacques BOUTROS
- Numero di telefono: 04 92 03 76 09
- Email: boutros.j@chu-nice.fr
-
Nîmes, Francia, 30029
- Reclutamento
- Institut de Cancérologie du Gard
-
Contatto:
- Sylvie VAN HULST
- Numero di telefono: 04 66 68 32 21
- Email: sylvie.vanhulst@chu-nimes.fr
-
Paris, Francia, 75014
- Reclutamento
- Hôpital Paris Saint- Joseph
-
Contatto:
- Charles NALTET
- Numero di telefono: 01 44 12 37 52
- Email: cnaltet@ghpsj.fr
-
Tarbes, Francia, 65000
- Reclutamento
- Polyclinique Ormeau
-
Contatto:
- Pierre-Marie PIALAT
- Numero di telefono: 05 62 93 59 29
- Email: dr.pialat@grop65.fr
-
-
Hauts-de-France
-
Creil, Hauts-de-France, Francia, 60100
- Reclutamento
- Institut de Radiothérapie du Sud de l'Oise
-
Contatto:
- Andres HUERTAS, MD
- Numero di telefono: +33 (0)3 44 28 41 00
- Email: andres.huertas@amethyst.fr
-
Investigatore principale:
- Andres HUERTAS, MD
-
-
Provence-Alpes-Côte d'Azur Region
-
Avignon, Provence-Alpes-Côte d'Azur Region, Francia, 84000
- Reclutamento
- Centre Sainte-Catherine
-
Contatto:
- Nicolas POUREL, MD
- Numero di telefono: +33 (0)4 90 27 60 28
- Email: n.pourel@isc84.org
-
Investigatore principale:
- Nicolas POUREL, MD
-
-
Île-de-France Region
-
Saint-Cloud, Île-de-France Region, Francia, 92210
- Reclutamento
- Institut Curie
-
Contatto:
- Maxime LOO
- Numero di telefono: 01 47 11 16 31
- Email: maxime.loo@curie.fr
-
Villejuif, Île-de-France Region, Francia, 94805
- Reclutamento
- Gustave Roussy
-
Investigatore principale:
- Antonin LÉVY, MD
-
Contatto:
- Antonin LÉVY, MD
- Numero di telefono: +33 (0)1 42 11 47 57
- Email: antonin.levy@gustaveroussy.fr
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically proven advanced synchronous oligometastatic stage IV NSCLC.
- NSCLC patients eligible first line immunotherapy-based SoC according to the European Marketing Authorization.
- PDL1 status available.
- Metastases eligible to RLT according to the local multidisciplinary board (MTB): ≤5cm each in CT scan, excluding primary tumour.
- Maximum 5 metastases in 3 organs (EORTC criteria), according to brain MRI and FDG-PET.
- Symptomatic lesions requiring urgent palliative radiation, is permitted prior to randomization. These treated lesions should be counted towards the total number of metastases at the time of enrolment.
- Clinically required brain metastases (BM) ablation (surgery and/or SBRT) is permitted and BM count within the total number of 5 lesions. The patient would then be randomized to treatment of their extracranial disease.
- Acceptable organ function for RLT.
- ECOG performance status (PS) 0-1.
- Measurable lesions according to RECIST V1.1 on standard imaging.
- Patient aged 18 or more.
- Woman of childbearing potential must agree to use adequate contraception (implant type, vaginal ring, contraceptive pill, contraceptive patch, Intrauterine Device (IUD), etc.) for the duration of study participation and up to 6 months after completing treatment/therapy, in addition, male partners use a condom during this same period. Male patients must agree to use condom for the duration of study participation and up to 6 months after completing treatment/therapy.
- Patients affiliated to the social security system.
- Patient should understand, sign, and date the informed consent form written in French prior to any protocol-specific procedures performed.
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits, and examinations including follow-up.
Exclusion Criteria:
- Non-squamous NSCLC with targetable tumour mutations and approved first line targeted therapy (such as EGFR, ALK and ROS1).
- Metastases not eligible to RLT: e.g. brainstem or diffuse serosal metastases (meningeal, pericardial, pleural, peritoneal, mesenteric) or that invades the gastrointestinal tract.
- Brain metastases only, without extra-cerebral metastases.
- Uncontrolled severe comorbidity, symptomatic interstitial lung disease or active infection.
- Prior therapy with T-cell costimulation or immune checkpoint-targeted agents within 1 year.
- Uncontrolled concomitant (<1-year) malignancy except adequately treated basal or squamous cell carcinoma of the skin, or in-situ carcinoma of any organ or in-situ melanoma of the skin.
- Persons deprived of liberty by judicial or administrative decision.
- Persons subject to a legal protection measure (guardianship, curatorship, safeguard of justice).
- Persons not affiliated to a social security system or equivalent.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Experimental arm: RLT + SoC-based immunotherapy (+/- chemotherapy)
RLT of all metastatic sites should be administered within 3 months after randomization and should not delay SoC-based immunotherapy administration. |
RLT of all metastatic sites. The possible RLT options will be SBRT, interventional radiology and/or minimally invasive surgery. Depending on the metastatic site, access and patient condition, the best RLT should be initially discussed in a case-to-case basis at the local multidisciplinary board (MTB). The primary tumour and initially invaded lymph nodes should be treated during the maintenance phase. Curative-intent approach modalities (e.g. hypofractionated intensity-modulated thoracic radiation therapy or surgery) should be discussed at the local MTB.
Altri nomi:
Current French SoC will be used. Main SoC-based immunotherapy includes:
Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association. Bevacizumab is not allowed given possible interactions with RLT. Maintenance/Immunotherapy alone will be pursued at the investigator's discretion according to the standard procedures (toxicity, progression, choice of the patient...). |
|
Comparatore attivo: Control arm: SoC-based immunotherapy (+/- chemotherapy)
SoC-based immunotherapy (+/- chemotherapy) will be administered every 3 weeks |
Current French SoC will be used. Main SoC-based immunotherapy includes:
Other alternatives include nivolumab-ipilimumab-chemotherapy or durvalumab-tremelimumab-chemotherapy association. Bevacizumab is not allowed given possible interactions with RLT. Maintenance/Immunotherapy alone will be pursued at the investigator's discretion according to the standard procedures (toxicity, progression, choice of the patient...). |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS).
Lasso di tempo: From date of randomization up to two years after the randomization of the last patient or documented death.
|
Time from randomization to the date of documented death from any cause or last follow-up. |
From date of randomization up to two years after the randomization of the last patient or documented death.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free survival (PFS) according to RECIST 1.1.
Lasso di tempo: From date of randomization up to two years after the randomization of the last patient or documented death.
|
Time between the randomization date and the date of observation of a progression of the disease according to RECIST 1.1 or death of the patient (all causes combined) or date of last follow-up if the patient is alive without progression or lost to follow up. |
From date of randomization up to two years after the randomization of the last patient or documented death.
|
|
immune Progression-free survival (iPFS) according to iRECIST.
Lasso di tempo: From date of randomization up to two years after the randomization of the last patient or documented death.
|
Time between the randomization date and the date of observation of an progression of the disease according to iRECIST 1.1 or death of the patient (all causes combined) or date of last follow-up if the patient is alive without progression or lost to follow up. |
From date of randomization up to two years after the randomization of the last patient or documented death.
|
|
Number of side effects measured by CTCAE V.5.
Lasso di tempo: From date of randomization up to two years after the randomization of the last patient or documented death.
|
Acute/ late adverse events graded by CTCAE v5 (toxic death and serious adverse events) and their imputability to treatment. |
From date of randomization up to two years after the randomization of the last patient or documented death.
|
|
EORTC Quality of Life Questionnaire-C30 (EORTC QLQ-C30).
Lasso di tempo: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
|
The EORTC Quality of Life Questionnaire-C30 (EORTC QLQ-C30) contains 30 questions and assesses the quality of life of oncological patients multidimensionally over 10 subscales. All sub-scales and the 6 individual items have a score range from 0 to 100 points. A higher score represents better function and a higher quality of life. In the symptom subscale, however, a higher score represents a higher level of symptoms or problems. |
From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
|
|
EORTC Quality of Life Questionnaire Lung Cancer-specific-13 (QLQ-LC-13).
Lasso di tempo: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
|
EORTC Quality of Life Questionnaire Lung Cancer-specific-13 (QLQ-LC-13) is a specific companion module used in conjunction with the EORTC QLQ-C30 and specifically developed for patients with Lung Cancer, and reliable in LC specific Qol assessment. The EORTC QLQ-LC13 comprises 13 item that measure lung cancer-related symptoms. Each items use the same 1-to-4 verbal response scale as the QLQ-C30 items, and domain scores are also transformed to a 0-to-100 metric. A higher score represents better function and a higher quality of life. |
From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
|
|
EuroQol-5D-5L Questionnaire (EQ-5D-5L).
Lasso di tempo: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
|
The EuroQol-5D-5L Questionnaire (EQ-5D-5L) descriptive system of 5 health dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Index scores range from -0.59 to 1; 1 is the best possible health state. Negative values represent health states perceived as worse than dead, which is equal to 0. Used alongside the EQ-5D, the EQ visual analog scale (VAS) is a 20 cm VAS "assessing your own health today" with endpoints labeled "Best imaginable health state" (100) and "Worst imaginable health state" (0). |
From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
|
|
Clearance of circulating tumour DNA (ctDNA).
Lasso di tempo: At the randomization, then Week 6 and Month 4 after randomization.
|
ctDNA assessed in plasma. |
At the randomization, then Week 6 and Month 4 after randomization.
|
|
Economic evaluation.
Lasso di tempo: From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
|
Incremental cost per Quality-adjusted life year (QALY based on EQ-5D-5L measures), incremental net monetary benefit. Assess the cost-utility (cost per QALY) of RLT + immunotherapy-based SoC compared to immunotherapy-based SoC alone. |
From date of randomization up to 24 months after the last patient included in the study, until the date of first documented progression or date of death from any cause, whichever come first.
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2023-503326-39-00
- 2023/3729 (Altro identificatore: CSET number (Gustave Roussy ID))
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .